Anx-131 | Original & Plus

ANX-131 is a . It gently reduces the overactive tonic current caused by these δ-subunits, allowing the brain’s natural phasic (on-demand) inhibition (via α1 and α2 subunits) to work properly again.

If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s. ANX-131

Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch. ANX-131 is a